“The current predicament has exposed some structural weaknesses during the EU’s medicines provide chain and a large dependence on non-EU nations around the world for active pharmaceutical ingredients,” Kyriakides claimed. She advisable that offer chain problems be resolved within an EU pharmaceutica

“The existing condition has exposed some structural weaknesses from the EU’s medicines supply chain in addition to a significant dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides reported. She proposed that offer chain issues be dealt with within an EU p